{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:19:01Z","timestamp":1790201941526,"version":"4.1.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000866","name":"International AIDS Vaccine Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000866","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Zaire ebolavirus (EBOV), Sudan ebolavirus (SUDV) and Marburg virus (MARV), are members of the <jats:italic>Filoviridae<\/jats:italic> family that can cause severe disease and death in humans and animals. The reemergence of Ebola, Sudan and Marburg virus disease highlight the need for continued availability of safe and effectives vaccines as well as development of new vaccines. While randomized controlled trials using disease endpoints provide the most robust assessment of vaccine effectiveness, challenges to this approach include the unpredictable size, location, occurrence and duration of filovirus disease outbreaks. Thus, other approaches to demonstrating vaccine effectiveness have been considered. These approaches are discussed using examples of preventive vaccines against other infectious diseases. In addition, this article proposes a clinical immunobridging strategy using licensed EBOV vaccines as comparators for demonstrating the effectiveness of filovirus vaccine candidates that are based on the same licensed vaccine platform technology.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1109486","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T09:26:38Z","timestamp":1675329998000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Approaches to demonstrating the effectiveness of filovirus vaccines: Lessons from Ebola and COVID-19"],"prefix":"10.3389","volume":"14","author":[{"given":"Marion F.","family":"Gruber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip R.","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1404505","article-title":"Emergence of Zaire Ebola virus disease in Guinea","volume":"371","author":"Baize","year":"2014","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/978-3-7091-7482-1_9","article-title":"Emerging and reemerging of filoviruses","volume":"11","author":"Feldmann","year":"1996","journal-title":"Arch Virol Suppl."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/v4020258","article-title":"Filovirus entry: a novelty in the viral fusion world","volume":"4","author":"Hunt","year":"2012","journal-title":"Viruses"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00565-15","article-title":"Niemann-pick C1 is essential for ebolavirus replication and pathogenesis in vivo","volume":"6","author":"Herbert","year":"2015","journal-title":"mBio"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nri2098","article-title":"How Ebola and marburg viruses battle the immune system","volume":"7","author":"Mohamadzadeh M","year":"2007","journal-title":"Nature Reviews immunology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir299","article-title":"Basic clinical and laboratory features of filoviral hemorrhagic fever","author":"Kortepeter","year":"2011","journal-title":"J Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1080\/21505594.2021.1898169","article-title":"Pathogenicity and virulence of ebolaviruses with species- and variant-specificity","volume":"12","author":"Yamaoka","year":"2021","journal-title":"Virulence"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.3390\/vaccines10081263","article-title":"Protection against marburg virus and Sudan virus in NHP by and adenovector-based trivalent vaccine regimen is correlated to humoral immune response levels","volume":"10","author":"Tiemess","year":"2022","journal-title":"Vaccines"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10081338","article-title":"Immune correlates of protection from filovirus efficacy studies in non-human primates","volume":"10","author":"Triplett","year":"2022","journal-title":"Vaccines (Basel)."},{"key":"B10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/nature19790","article-title":"The evolution of Ebola virus: Insights from the 2013-2016 epidemic","volume":"538","author":"Holmes","year":"2016","journal-title":"Nature"},{"key":"B11","unstructured":"First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response2019"},{"key":"B12","unstructured":"Ervebo2019"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomized trial (Ebola Ca suffit","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":") Lancet"},{"key":"B14","unstructured":"New vaccine for prevention of Ebola virus disease recommended for approval in the European union2020"},{"key":"B15","unstructured":"Safety of two Ebola virus vaccines2015"},{"key":"B16","unstructured":"Marburg virus - Ghana2022"},{"key":"B17","unstructured":"Ebola Disease caused by Sudan virus - Uganda2022"},{"key":"B18","unstructured":"DENGVAXIA2020"},{"key":"B19","unstructured":"Vaccines licensed for use in the united states comirnaty2021"},{"key":"B20","unstructured":"Vaccines licensed for use in the united states spikevax2021"},{"key":"B21","unstructured":"HEPLISAV-b2020"},{"key":"B22","unstructured":"CFR - code of federal regulations title 212022"},{"key":"B23","unstructured":"Clinical data needed to support licensure od seasonal inactivated influenza vaccines2007"},{"key":"B24","unstructured":"Vaccines and related biological products advisory committee November 8, 2019 meeting announcement2019"},{"key":"B25","unstructured":"Conditional marketing authorization2006"},{"key":"B26","unstructured":"Guideline on procedures for the granting of a marketing authorization under exceptional circumstances pursuant to article 14 (8) of regulation (EC) no.726\/20042005"},{"key":"B27","unstructured":"CanadaH\n          Submission and information requirements for extraordinary use new drugs (EUNDs)2014"},{"key":"B28","unstructured":"CFR - code of federal regulations title 21 6012022"},{"key":"B29","doi-asserted-by":"publisher","first-page":"16013","DOI":"10.1038\/npjvaccines.2016.13","article-title":"First vaccine approval under the FDA animal rule","volume":"1","author":"Beasley","year":"2016","journal-title":"NPJ Vaccines"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10101582","article-title":"Nonhuman primates are proteced against marburg virus disease by vaccination with a vesicular stomatitis virus vector-based vaccine prepared under conditions to allow advancement to human clinical trials","volume":"10","author":"Cooper","year":"2022","journal-title":"Vaccines"},{"key":"B31","unstructured":"Emergency use authorization for vaccines to prevent COVID-192022"},{"key":"B32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clincial trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"key":"B33","unstructured":"CanadaGo\n          Access consortium: Alignment with ICMRA consensus on immunobridging for authorizing new COVID-19 vaccines2021"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.07.028","article-title":"Making more COVID-19 vaccines available to address global needs: Considerations and a framework for their evaluation","volume":"40","author":"Krause","year":"2022","journal-title":"Vaccine"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.07.044","article-title":"Antibody repertoires to the same Ebola vaccine antigen are differentially affected by vaccine vectors","volume":"24","author":"Meyer","year":"2018","journal-title":"Cell Rep"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.3390\/v14102291","article-title":"Natural history of marburg virus infection to support medical countermeasure development","volume":"14","author":"Comer","year":"2022","journal-title":"Viruses"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10060963","article-title":"Natural history of Sudan ebolavirus to support medical countermeasure development","volume":"10","author":"Carbonnelle","year":"2022","journal-title":"Vaccines"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252874","article-title":"Natural history of disease in cynomolgus monkeys exposed to Ebola virus kikwit strain demonstrates the reliability of this non-human primate model for Ebola virus disease","volume":"16","author":"Niemuth","year":"2021","journal-title":"PloS One"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2022.2086072","article-title":"Natural history of Sudan ebolavirus infection in rhesus and cynomolgus macaques","volume":"11","author":"Woolsey","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63591-2","article-title":"Pathogenesis and Ebola hemorrhagic fever in cynomolgus macaques: evidence that dentritic cells are early and sustained targets of infection","volume":"163","author":"Geisbert","year":"2003","journal-title":"Am J Pathol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(20)30198-1","article-title":"Estimation of the correlates of protection of the rVSVG-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2\/3 clinical trials","volume":"2","author":"Grais","year":"2021","journal-title":"Lancet Microbe"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/nature17949","article-title":"Unique human immune signature of Ebola virus disease in Guinea","volume":"533","author":"Ruibal","year":"2016","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"crossref","unstructured":"RadinskyO\n            EdriA\n            BrusilovskyM\n            Fedida-MetulaS\n            SobarzoA\n            Gershoni-yahalomO\n          Sudan Ebolavirus long recovered survivors produce GP-specific abs that are of the IgG1 subclass and preferentially bind fc gamma RI2017","DOI":"10.1038\/s41598-017-06226-8"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.599568","article-title":"Ebolavirus: Comparison of survivor immunology and animal models in the search for a correlate of protection","volume":"11","author":"Longet","year":"2020","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2447","article-title":"CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates","volume":"17","author":"Sullivan","year":"2011","journal-title":"Nat Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrmicro2129","article-title":"Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule","volume":"7","author":"Sullivan","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.0030002","article-title":"Effective post-exposure treatment of Ebola infection","volume":"3","author":"Feldmann","year":"2007","journal-title":"PloS Pathog"},{"key":"B48","doi-asserted-by":"publisher","first-page":"6894","DOI":"10.1016\/j.vaccine.2008.09.082","article-title":"Vesicular stomatitis virus-based vaccines protect nonhuman promates against aerosol challenge with Ebola and marburg vaccines","volume":"26","author":"Geisbert","year":"2008","journal-title":"Vaccine"},{"key":"B49","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.cell.2017.04.037","article-title":"Antibodies from a human survivor define sites of vulnerability for broad protection against ebolaviruses","volume":"169","author":"Wec","year":"2017","journal-title":"Cell"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad5788","article-title":"Isolation of potent neutralizing antibody titers from a survivor of the 2014 Ebola virus outbreak","volume":"351","author":"Bornholdt","year":"2016","journal-title":"Science"},{"key":"B51","unstructured":"FDA Approves first treatment for Ebola virus2020"},{"key":"B52","unstructured":"FDA Approves treatment for ebola virus2020"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1109486\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T09:26:47Z","timestamp":1675330007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1109486\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,2]]},"references-count":52,"alternative-id":["10.3389\/fimmu.2023.1109486"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1109486","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,2]]},"article-number":"1109486"}}